Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Ett försök för att bedöma Cobicistat Boost Venetoclax i kombination med azacitidin hos vuxna patienter med nydiagnostiserad AML (HO171)

En enarmsfas II-studie för att bedöma Cobicistat Boosted Venetoclax i kombination med azacitidin (sc) hos vuxna patienter med nyligen diagnostiserad akut myeloid leukemi (AML) som inte anses vara kandidater för intensiva behandlingsregimer

The treatment of older unfit patients with acute myeloid leukemia (AML) is challenging. The hypomethylating agents (HMA) azacitidine and decitabine have relatively mild side effects and have proven to be feasible for the treatment of older patients and patients with co-morbidities. Currently, venetoclax added to an HMA agent is the new standard of treatment. Since this new standard comes with a substantial societal financial burden, there is a rational to optimize the venetoclax dosing schedule. The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure, thereby allowing to reduce the dose of venetoclax and thus costs substantially.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

142

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Gerwin Huls, prof
  • Telefonnummer: +3150 361 2354
  • E-post: g.huls@umcg.nl

Studieorter

      • 's-Hertogenbosch, Nederländerna
        • Rekrytering
        • NL-Den Bosch-JBZ
        • Kontakt:
          • A.H.E. Herbers, Dr.
      • Amersfoort, Nederländerna
        • Rekrytering
        • NL-Amersfoort-MEANDERMC
        • Kontakt:
          • M.F. Corsten, Dr.
      • Amsterdam, Nederländerna
        • Rekrytering
        • NL-Amsterdam-OLVG
        • Kontakt:
          • H. Mooij, Dr.
      • Amsterdam, Nederländerna
        • Rekrytering
        • NL-Amsterdam-AUMC
        • Kontakt:
          • C. Alhan, Dr.
      • Arnhem, Nederländerna
        • Rekrytering
        • NL-Arnhem-RIJNSTATE
        • Kontakt:
          • M.L.H. Cuijpers, Dr.
      • Breda, Nederländerna
        • Rekrytering
        • NL-Breda-AMPHIA
        • Kontakt:
          • R.B. Fiets, Dr.
      • Dordrecht, Nederländerna
        • Rekrytering
        • NL-Dordrecht-ASZ
        • Kontakt:
          • P.E. Westerweel, Dr.
      • Eindhoven, Nederländerna
        • Rekrytering
        • NL-Eindhoven-MAXIMAMC
        • Kontakt:
          • L.W. Tick, Dr.
      • Eindhoven, Nederländerna
        • Rekrytering
        • NL-Eindhoven-CATHARINA
        • Kontakt:
          • M.J. Cruijsen, Dr.
      • Enschede, Nederländerna
        • Rekrytering
        • NL-Enschede-MST
        • Kontakt:
          • T.J.F. Snijders, Dr.
      • Groningen, Nederländerna
        • Rekrytering
        • NL-Groningen-UMCG
        • Kontakt:
          • G.A. Huls, Prof. dr.
      • Leeuwarden, Nederländerna
        • Rekrytering
        • NL-Leeuwarden-MCL
        • Kontakt:
          • B. Franken, Dr.
      • Leiden, Nederländerna
        • Rekrytering
        • NL-Leiden-LUMC
        • Kontakt:
          • P.A. von dem Borne, Dr.
      • Maastricht, Nederländerna
        • Rekrytering
        • NL-Maastricht-MUMC
        • Kontakt:
          • C.H.M.J. van Elssen, Dr.
      • Nieuwegein, Nederländerna
        • Rekrytering
        • NL-Nieuwegein-ANTONIUS
        • Kontakt:
          • O. de Weerdt, Dr.
      • Nijmegen, Nederländerna
        • Rekrytering
        • NL-Nijmegen-RADBOUDUMC
        • Kontakt:
          • N.A. de Jonge, Dr.
      • Nijmegen, Nederländerna
        • Rekrytering
        • NL-Nijmegen-CWZ
        • Kontakt:
          • S. de Jonge, Dr.
      • The Hague, Nederländerna
        • Rekrytering
        • NL-Den Haag-HAGA
        • Kontakt:
          • D. van Lammeren, Dr.
      • Zwolle, Nederländerna
        • Rekrytering
        • NL-Zwolle-ISALA
        • Kontakt:
          • T.T. de Waal, Dr.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

  • Patients with: a diagnosis of AML and related precursor neoplasms according to ICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A). Patients may have had previous treatment with erythropoiesis stimulating agents (ESA) for an antecedent phase of MDS. ESAs must be stopped at least two weeks before registration.

  • Patients 18 years and older who are considered not fit for intensive chemotherapy or who decline the option of intensive chemotherapy.

  • WHO performance status 0, 1 or 2 (appendix E).

  • Leukocytes < 30 x109/L

  • Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:

    • Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
    • Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome.
    • Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
  • Male subjects who are sexually active, must agree, from Study Day 1 until at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.

  • Female subjects must be either postmenopausal defined as: Age >55 years with no menses for ≥12 months, without an alternative medical cause. OR willing and able to use adequate contraception during and until 180 days after the last protocol treatment.

  • Written informed consent.

  • Patient is capable of giving informed consent.

  • Patient agrees not to participate in another interventional study while on treatment without approval of the (co-) Principal Investigator.

Exclusion Criteria:

A patient who meets any of the following criteria cannot be included in this study:

  • Acute promyelocytic leukemia.

  • Myelodysplastic syndrome (MDS).

  • Patients previously treated for AML or MDS (any anti-leukemic therapy including investigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2) hydroxyurea ((previous treatment with hydroxyurea is allowed for the control of peripheral leukemic blasts in patients with leukocytosis).

  • Diagnosis of any previous or concomitant malignancy is an exclusion criterion:

    • except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration;
    • except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
  • Blast crisis of chronic myeloid leukemia.

  • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.).

  • Cardiac dysfunction as defined by:

    • Myocardial infarction within the last 3 months of study entry, or
    • Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or
    • Unstable angina or New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix G), or
    • Unstable cardiac arrhythmias.
  • History of stroke or intracranial haemorrhage within 6 months prior to registration.

  • Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement).

  • History of non-compliance to medical regimens or considered unreliable with respect to compliance.

  • Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.

  • Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea.

  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

  • Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrates with a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment). Please check with Appendix I.

  • Intolerability, contra-indication or allergy to one of the study drugs.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: single arm arm extension phase

prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1

during run-in and extention phase: from Cycle 1 until relapse

during run-in and extention phase: from Cycle 1 until relapse

during run-in phase: from cycle 2 until relapse

during extension phase: from cycle 1 until relapse

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacokinetic equivalence of cobicistat boosted venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).
Tidsram: 6-8 months

run-in phase

6-8 months
Overall survival (OS).
Tidsram: 48 months

extension phase

48 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Venetoclax and cobicistat CL, Cmax, Tmax, Cmin and AUC0-24.
Tidsram: 6-8 months

run-in phase

6-8 months
Complete remission (CR) rate defined as CR as best response during or at completion of the treatment, as determined by the Investigator, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsram: 48 months

extension phase

48 months
CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsram: 48 months

extension phase

48 months
CR and CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsram: 48 months

extension phase

48 months
CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsram: 48 months

extension phase

48 months
CR and CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsram: 48 months

extension phase

48 months
CR or CR/CRi or CR/CRh without minimal residual disease (flow and or molecular) (CRMRD- or CR/CRiMRD- or CR/CRhMRD-).
Tidsram: 48 months

extension phase

48 months
Morphologic leukemia-free state (MLFS) rate, based on ELN2022 recommendations.
Tidsram: 48 months

extension phase

48 months
Event free survival (EFS).
Tidsram: 48 months

extension phase

48 months
Relapse-free survival (RFS).
Tidsram: 48 months

extension phase

48 months
Incidence and severity of adverse events according to CTCAE version 5.0.
Tidsram: 48 months

extension phase

48 months
Early (30-day and 60-day) mortality (in general, non-leukemic).
Tidsram: 48 months

extension phase

48 months
Time to next cycle, defined as the time from the start of the cycle until the start of the next cycle.
Tidsram: 48 months

extension phase

48 months
OS of AZA/VEN/COBI treated patients in comparison with a real-world data cohort treated during the same time period and monitored by the Dutch Cancer registry.
Tidsram: 48 months

extension phase

48 months
Prognostic/predictive impact of disease-associated genetic changes at diagnosis.
Tidsram: 48 months

extension phase

48 months
Relapse-associated genetic changes (determined at relapse). The average relative dose intensity will be computed and given by categories. The same will be done for treatment deviation.
Tidsram: 48 months

extension phase

48 months
Clonal evolution during treatment.
Tidsram: 48 months

extension phase

48 months
Exposure-response and exposure-toxicity relation of venetoclax in patients with AML.
Tidsram: 48 months

extension phase

48 months
Cost-savings on venetoclax drug costs.
Tidsram: 48 months

extension phase

48 months
Adherence to venetoclax and cobicistat.
Tidsram: 48 months

extension phase

48 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 januari 2024

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 december 2028

Studieregistreringsdatum

Först inskickad

4 juli 2023

Först inskickad som uppfyllde QC-kriterierna

23 augusti 2023

Första postat (Faktisk)

28 augusti 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera